- Home
- CSTL vs CVAC Comparison
CSTL vs CVAC Comparison
Compare CSTL & CVAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CSTL
- CVAC
- Stock Information
- Founded
- CSTL 2007
- CVAC 2000
- Country
- CSTL United States
- CVAC Germany
- Employees
- CSTL N/A
- CVAC N/A
- Industry
- CSTL Medical Specialities
- CVAC Biotechnology: Pharmaceutical Preparations
- Sector
- CSTL Health Care
- CVAC Health Care
- Exchange
- CSTL Nasdaq
- CVAC Nasdaq
- Market Cap
- CSTL 848.1M
- CVAC 818.8M
- IPO Year
- CSTL 2019
- CVAC 2020
- Fundamental
- Price
- CSTL $25.75
- CVAC $3.30
- Analyst Decision
- CSTL Strong Buy
- CVAC Hold
- Analyst Count
- CSTL 6
- CVAC 3
- Target Price
- CSTL $40.33
- CVAC $10.00
- AVG Volume (30 Days)
- CSTL 358.8K
- CVAC 656.5K
- Earning Date
- CSTL 02-27-2025
- CVAC 11-12-2024
- Dividend Yield
- CSTL N/A
- CVAC N/A
- EPS Growth
- CSTL N/A
- CVAC N/A
- EPS
- CSTL 0.21
- CVAC N/A
- Revenue
- CSTL $311,878,000.00
- CVAC $70,565,734.00
- Revenue This Year
- CSTL $51.99
- CVAC $742.57
- Revenue Next Year
- CSTL N/A
- CVAC N/A
- P/E Ratio
- CSTL $122.41
- CVAC N/A
- Revenue Growth
- CSTL 62.43
- CVAC 75.11
- 52 Week Low
- CSTL $16.97
- CVAC $2.22
- 52 Week High
- CSTL $35.84
- CVAC $5.28
- Technical
- Relative Strength Index (RSI)
- CSTL 37.34
- CVAC 39.12
- Support Level
- CSTL $26.65
- CVAC $3.53
- Resistance Level
- CSTL $28.48
- CVAC $3.72
- Average True Range (ATR)
- CSTL 1.12
- CVAC 0.18
- MACD
- CSTL -0.17
- CVAC -0.06
- Stochastic Oscillator
- CSTL 0.94
- CVAC 10.96
About CSTL Castle Biosciences Inc.
Castle Biosciences Inc is a commercial-stage dermatological cancer company. It is focused on providing physicians and their patients with personalized, clinically actionable genomic information to make more accurate treatment decisions. The product portfolio of the company includes Cutaneous Melanoma, DecisionDx-Melanoma, DecisionDx-CMSeq, and DecisionDx-PRAME among others.
About CVAC CureVac N.V.
CureVac is a biopharmaceutical company headquartered in Germany that is developing vaccines and therapies using messenger ribonucleic acid, or mRNA. The company was founded in 2000 and had its initial public offering in August 2020. CureVac had a collaboration with GSK to develop second-generation seasonal influenza and Covid vaccines and an avian influenza vaccine. The company's other pipeline candidates include mRNA vaccines for oncology and molecular therapies spanning tumors, liver, and ocular diseases.